Keywords: banyu, sees, delay, fosamax, japan, merck, co

Banyu sees delay for Fosamax in Japan

Article | 17 November 2000

Print This

Merck & Co's Japanese subsidiary Banyu has announced that Fosamax(alendronate) for osteoporosis will not be approved this year, but the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in